Cargando…

Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager

There are limited strategies for the treatment of hepatocellular carcinoma (HCC). In this study, we prepared a Bispecific T cell engager (BiTE) targeting Glypican 3 (GPC3) and CD3. The GPC3/CD3 BiTE was prepared by fusing the single-chain variable fragment (scFv) of the humanized anti-GPC3 antibody...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bi, Yanyu, Jiang, Hua, Wang, Peng, Song, Bo, Wang, Huamao, Kong, Xianming, Li, Zonghai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581077/ https://www.ncbi.nlm.nih.gov/pubmed/28881778 http://dx.doi.org/10.18632/oncotarget.17905

Ejemplares similares

Bispecific GPC3/PD-1 CAR-T cells for the treatment of HCC
por: Li, Dezhi, et al.
Publicado: (2023)

Combined local therapy and CAR‐GPC3 T‐cell therapy in advanced hepatocellular carcinoma: a proof‐of‐concept treatment strategy
por: Shi, Yaoping, et al.
Publicado: (2023)

Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma
por: Ofuji, Kazuya, et al.
Publicado: (2014)

GPC-3 in hepatocellular carcinoma: current perspectives
por: Wu, Yongle, et al.
Publicado: (2016)

Low glucose metabolism in hepatocellular carcinoma with GPC3 expression
por: Li, You-Cai, et al.
Publicado: (2018)

Targeted Therapy of Hepatocellular Carcinoma Using Gemcitabine-Incorporated GPC3 Aptamer
por: Park, Jun Young, et al.
Publicado: (2020)

Targeted-detection and sequential-treatment of small hepatocellular carcinoma in the complex liver environment by GPC-3-targeted nanoparticles
por: Deng, Han, et al.
Publicado: (2022)

Significance of Glypican-3 (GPC3) Expression in Hepatocellular Cancer Diagnosis
por: Sun, Bin, et al.
Publicado: (2017)

Preparation and Characterization of Anti-GPC3 Nanobody Against Hepatocellular Carcinoma
por: Xia, Lijie, et al.
Publicado: (2020)

Highly Potent Immunotoxins Targeting the Membrane-distal N-lobe of GPC3 for Immunotherapy of Hepatocellular Carcinoma
por: Li, Jingwen, et al.
Publicado: (2022)

A GPC3-specific aptamer-mediated magnetic resonance probe for hepatocellular carcinoma
por: Zhao, Menglong, et al.
Publicado: (2018)

Combination of AAV-CCL19 and GPC3 CAR-T Cells in the Treatment of Hepatocellular Carcinoma
por: Meng, Min, et al.
Publicado: (2021)

Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma
por: Jiang, Zhiwu, et al.
Publicado: (2017)

Chimeric anti-GPC3 sFv-CD3ε receptor-modified T cells with IL7 co-expression for the treatment of solid tumors
por: Sun, Yansha, et al.
Publicado: (2022)

Phosphorothioate-Modified AP613-1 Specifically Targets GPC3 when Used for Hepatocellular Carcinoma Cell Imaging
por: Dong, Lili, et al.
Publicado: (2018)

The clinical significance of CTC enrichment by GPC3-IML and its genetic analysis in hepatocellular carcinoma
por: Yi, Bin, et al.
Publicado: (2021)

Clinical values of AFP, GPC3 mRNA in peripheral blood for prediction of hepatocellular carcinoma recurrence following OLT: AFP, GPC3 mRNA for prediction of HCC
por: Wang, Yuliang, et al.
Publicado: (2011)

Structure based innovative approach to analyze aptaprobe–GPC3 complexes in hepatocellular carcinoma
por: Shin, Woo-Ri, et al.
Publicado: (2022)

Correction to: The clinical significance of CTC enrichment by GPC3-IML and its genetic analysis in hepatocellular carcinoma
por: Yi, Bin, et al.
Publicado: (2021)

Natural killer cells modified with a Gpc3 aptamer enhance adoptive immunotherapy for hepatocellular carcinoma
por: Zheng, Youshi, et al.
Publicado: (2023)

GPC6 Promotes Cell Proliferation, Migration, and Invasion in Nasopharyngeal Carcinoma
por: Fan, Chunmei, et al.
Publicado: (2019)

Derivation and Preclinical Characterization of CYT-303, a Novel NKp46-NK Cell Engager Targeting GPC3
por: Arulanandam, Antonio, et al.
Publicado: (2023)

GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
por: Park, Jeong A., et al.
Publicado: (2020)

GPC3 affects the prognosis of lung adenocarcinoma and lung squamous cell carcinoma
por: Ning, Jing, et al.
Publicado: (2021)

Optimization of GPC3-specific chimeric antigen receptor structure and its effect on killing hepatocellular carcinoma cells
por: Zhao, Jianfeng, et al.
Publicado: (2021)

Research on the Construction of Bispecific-Targeted Sustained-Release Drug-Delivery Microspheres and Their Function in Treatment of Hepatocellular Carcinoma
por: Huang, Zi−Li, et al.
Publicado: (2022)

Preparation and in vitro studies of MRI-specific superparamagnetic iron oxide antiGPC3 probe for hepatocellular carcinoma
por: Li, Youwei, et al.
Publicado: (2012)

Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor
por: Fu, Mingpeng, et al.
Publicado: (2019)

Bispecific T-Cell Engagers Targeting Membrane-Bound IgE
por: Rodak, Aleksandra, et al.
Publicado: (2021)

The landscape of bispecific T cell engager in cancer treatment
por: Zhou, Shujie, et al.
Publicado: (2021)

Characterization of a novel bispecific antibody targeting tissue factor-positive tumors with T cell engagement
por: Pan, Zhidi, et al.
Publicado: (2022)

ENGINEERING T CELLS TARGETING GPC2 FOR TREATING NEUROBLASTOMA
por: Quan, Alex, et al.
Publicado: (2023)

Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII(+)PTEN(−) glioblastoma in vivo
por: Xu, Wen, et al.
Publicado: (2016)

Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
por: Sawada, Yu, et al.
Publicado: (2016)

GPC3 gene expression and allelic discrimination of FZD7 gene in Egyptian patients with hepatocellular carcinoma
por: Ramadan, Amany, et al.
Publicado: (2023)

Correction to: GPC3 affects the prognosis of lung adenocarcinoma and lung squamous cell carcinoma
por: Ning, Jing, et al.
Publicado: (2021)

Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma
por: Tang, Xiaolong, et al.
Publicado: (2018)

Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies
por: Hoseini, Sayed Shahabuddin, et al.
Publicado: (2020)

GPC3 Promotes Lung Squamous Cell Carcinoma Progression and HLA-A2-Restricted GPC3 Antigenic Peptide-Modified Dendritic Cell-Induced Cytotoxic T Lymphocytes to Kill Lung Squamous Cell Carcinoma Cells
por: Ning, Jing, et al.
Publicado: (2023)

Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies
por: Loh, Han Ping, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q77ub2e3u3a2pech7vs68ps4vq